Jean-Frédéric Blanc

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

Andrew X. Zhu, Masatoshi Kudo, Eric Assénat et al. · JAMA · 2014 · 569 citations · Full text

Medicine, Oncology, Pharmacology +17

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 164 citations · Full text

Medicine, Infectious Diseases, Oncology +14

Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes

Corinne Frère, Barbara Bournet, Sophie Gourgou et al. · Gastroenterology · 2019 · 90 citations · Full text

Medicine, Oncology, Surgery +16

Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis

Julien Edeline, Laurence Crouzet, Boris Campillo‐Gimenez et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 86 citations

Medicine, Oncology, Radiation Oncology +13